Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide

• Príomhchruthaitheoirí: A. S. Ametov (Údar), I. E. Shokhin (Údar), E. A. Rogozhina (Údar), T. G. Bodrova (Údar), M. E. Nevretdinova (Údar), P. A. Bely (Údar), K. Ya. Zaslavskaya (Údar), V. S. Scherbakova (Údar), D. V. Kurkin (Údar), K. N. Koryanova (Údar), E. S. Mishchenko (Údar), E. Yu. Kesova (Údar), E. D. Kozlov (Údar), E. S. Samoshkina (Údar), D. N. Andreev (Údar), Yu. G. Kazaishvili (Údar), S. M. Noskov (Údar), L. A. Balykova (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute, 2024-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Semaglutide is a representative of analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently used in Russia for the treatment of type 2 diabetes mellitus (T2DM; in monotherapy and in combination therapy), including patients with obesity and overweight.The aim of the wo...